AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD
Switzerland's health authority Swissmedic has given the Swiss-based pharmaceuticals group Novartis AG approval to market its Glivec drug as a treatment of adult patients with gastro-intestinal stromal tumours (GISTs), a malignant form of sarcoma.
Glivec is already approved in Switzerland and several other countries as a treatment of chronic myeloid leukaemia. The drug's mechanism of action involves a selective inhibition of enzymes that are responsible for the growth of …